New Non-Invasive Assay May Improve Surveillance of Heart and Other Solid-Organ Transplants (IMAGE)

Elsevier Health Sciences

New Non-Invasive Assay May Improve Surveillance of Heart and Other Solid-Organ Transplants

Caption

In solid organ transplant recipients, analysis of circulating cell-free DNA (cfDNA) offers advantages over invasive tissue biopsies for detection of rejection and immunotherapy surveillance. A by-product of cell death, cfDNA can be used to assess allograft injury by measuring donor-derived cfDNA (dd-cfDNA) against the background of recipient cfDNA. dd-cfDNA is quantified by analytically validated clinical-grade next-generation sequencing assay utilizing single nucleotide polymorphisms distributed across the genome to differentiate donor and recipient cfDNA.

Credit

CareDx, Inc.

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.